Literature DB >> 19840990

Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts.

J van Disseldorp1, C B Lambalk, J Kwee, C W N Looman, M J C Eijkemans, B C Fauser, F J Broekmans.   

Abstract

BACKGROUND: The antral follicle count (AFC) and anti-Müllerian hormone (AMH) both represent age-related follicular decline quite accurately, although long-term follow-up studies are still lacking. The best ovarian reserve test would need only a single, cycle-independent measurement to be representative.
METHODS: To compare the inter- and intra-cycle stability of AFC and AMH, we used age-adjusted intra-class correlation coefficients (ICCs). To measure inter-cycle stability across a number of up to four menstrual cycles, we used data, prospectively collected for the purpose of an other study, from 77 regularly cycling, infertile women aged 24-40 years. AMH and AFC values were measured on cycle day 3. To study intra-cycle variability, we used data from a prospective cohort study of 44 regularly cycling volunteers, aged 25-46 years and measured AMH and assessed the AFC (2-10 mm) every 1-3 cycle days.
RESULTS: Between menstrual cycles, AFC and AMH varied between 0 and 25 follicles (median 10), and 0.3 and 27.1 ng/ml (median 4.64). The difference in age-adjusted ICC between AMH [ICC, 0.89 (95% CI, 0.84-0.94)] and AFC [ICC, 0.71 (95% CI, 0.63-0.77)] was 0.18 (95% CI, 0.12-0.27). For the intra-cycle variation, 0-43 antral follicles (median 7) were counted per volunteer. The difference in age-adjusted ICC between AMH [ICC, 0.87 (95% CI, 0.82-0.91)] and AFC [ICC, 0.69 (95% CI, 0.46-0.82)] was 0.18 (95% CI, 0.034-0.42).
CONCLUSIONS: Serum AMH demonstrated less individual intra- and inter-cycle variation than AFCs and may therefore be considered a more reliable and robust means of assessing ovarian reserve in subfertile women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840990     DOI: 10.1093/humrep/dep366

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  62 in total

Review 1.  Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy--clinical approach and unsolved issues.

Authors:  Katharina Hancke; Vladimir Isachenko; Evgenia Isachenko; Jürgen M Weiss
Journal:  Support Care Cancer       Date:  2011-09-23       Impact factor: 3.603

Review 2.  Premature ovarian insufficiency: from pathogenesis to clinical management.

Authors:  S Luisi; C Orlandini; C Regini; A Pizzo; F Vellucci; F Petraglia
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

3.  Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore.

Authors:  Ryan Wai Kheong Lee; Lay Wai Khin; Marianne Sybille Hendricks; Heng Hao Tan; Sadhana Nadarajah; Nancy Wen Sim Tee; Seong-Feei Loh; Bee Choo Tai; Jerry Ky Chan
Journal:  Singapore Med J       Date:  2020-09       Impact factor: 1.858

4.  Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved.

Authors:  Francesca Filippi; Fabio Martinelli; Alessio Paffoni; Marco Reschini; Francesco Raspagliesi; Edgardo Somigliana
Journal:  J Assist Reprod Genet       Date:  2018-11-26       Impact factor: 3.412

5.  Serum antimüllerian hormone in healthy premenopausal women.

Authors:  Christiana M Shaw; Frank Z Stanczyk; Brian L Egleston; L L Kahle; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

Review 6.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

7.  Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2010-06-17       Impact factor: 5.211

Review 8.  Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium.

Authors:  Wendy van Dorp; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Marry M van den Heuvel-Eibrink; Marleen H van den Berg; Jennifer M Levine; Eline van Dulmen-den Broeder; Natascia di Iorgi; Assunta Albanese; Saro H Armenian; Smita Bhatia; Louis S Constine; Andreas Corrias; Rebecca Deans; Uta Dirksen; Clarisa R Gracia; Lars Hjorth; Leah Kroon; Cornelis B Lambalk; Wendy Landier; Gill Levitt; Alison Leiper; Lillian Meacham; Alesandro Mussa; Sebastian J Neggers; Kevin C Oeffinger; Alberto Revelli; Hanneke M van Santen; Roderick Skinner; Andrew Toogood; William H Wallace; Riccardo Haupt
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

Review 9.  Elecsys(®) AMH Assay: A Review in Anti-Müllerian Hormone Quantification and Assessment of Ovarian Reserve.

Authors:  Emma D Deeks
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

10.  Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.

Authors:  Hui-Chun Irene Su; Carolyn Haunschild; Karine Chung; Sara Komrokian; Sarah Boles; Mary Dupuis Sammel; Angela DeMichele
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.